Study guide

14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

Key Takeaways Explain This Topic AI

Generalized Anxiety Disorder (GAD) requires persistent, excessive worry across multiple life domains for at least 6 months with somatic symptoms, treated first-line with SSRIs/SNRIs and Cognitive Behavioral Therapy (CBT), while benzodiazepines are reserved strictly for short-term crisis management.

Alcohol withdrawal progresses through distinct physiological stages: minor autonomic symptoms (6-12 hours), hallucinosis with clear sensorium (12-24 hours), generalized tonic-clonic seizures (about 8–48 hours; peak near 24 hours), and Delirium Tremens (48-96 hours), which requires monitored IV benzodiazepines and objective assessment such as RASS/MINDS; CIWA-Ar is unsuitable during delirium.

Suspected Wernicke encephalopathy (confusion, gait ataxia and ocular abnormalities) requires prompt high-dose parenteral thiamine. Treat hypoglycaemia immediately with glucose; give thiamine concurrently when available, without delaying glucose while it is obtained.

Neuroleptic Malignant Syndrome (NMS) presents with hyperthermia, severe 'lead-pipe' rigidity, autonomic instability, and massive creatine kinase elevation (> 1000-10,000 U/L), managed by immediate drug cessation, ICU cooling, dantrolene, and bromocriptine; in contrast, Serotonin Syndrome is distinguished by prominent neuromuscular excitation, spontaneous or inducible clonus, and hyperreflexia.

In acute cocaine toxicity, use benzodiazepines first and vasodilators for persistent hypertension/ischemia. Avoid pure beta-blockers such as propranolol/metoprolol as initial therapy; specialist-selected alpha/beta blockade may be considered for persistent hyperadrenergic symptoms after initial treatment.

Last updated: November 2026

Anxiety & Stress-Related Disorders: Spectrum & Evidence-Based Management

Anxiety disorders represent the most prevalent class of psychiatric conditions worldwide. Clinicians must distinguish pathological, disabling anxiety from adaptive physiological fear and systematically address comorbid somatic manifestations.

1. Generalized Anxiety Disorder (GAD)

DSM-5 Criteria: Characterized by excessive, pervasive anxiety and worry about a multitude of everyday events or activities, occurring more days than not for at least 6 months , which the patient finds difficult to control. Accompanied by at least 3 of the following 6 somatic/cognitive symptoms (only 1 required in children):

  • Restlessness or feeling keyed up or on edge
  • Being easily fatigued
  • Difficulty concentrating or mind going blank
  • Irritability
  • Muscle tension (prominent neck, shoulder, or back stiffness)
  • Sleep disturbance (difficulty falling or staying asleep, restless unsatisfying sleep)

First-Line Therapy: First-line pharmacotherapy consists of SSRIs (sertraline, escitalopram) or SNRIs (venlafaxine, duloxetine). First-line psychotherapy is Cognitive Behavioral Therapy (CBT) . Second-line agents include Buspirone (a 5-HT1A receptor partial agonist; advantages: no sedation, no cognitive impairment, zero abuse or dependence potential; disadvantage: delayed therapeutic onset of 2 to 4 weeks, ineffective for panic disorder) and pregabalin. Benzodiazepines are restricted strictly to 1 to 2 weeks for acute severe crisis relief during SSRI initiation.

2. Panic Disorder & Agoraphobia

Panic Attack Phenomenology: An abrupt surge of intense fear or intense discomfort that peaks within minutes, accompanied by at least 4 of 13 somatic/cognitive symptoms : palpitations/tachycardia, diaphoresis, trembling/shaking, sensations of shortness of breath/smothering, feelings of choking, chest pain/discomfort, nausea/abdominal distress, dizziness/lightheadedness, chills/heat sensations, paresthesias (numbness/tingling), derealization/depersonalization, fear of losing control or 'going crazy', and fear of dying.

Panic Disorder Diagnostic Criteria: Recurrent unexpected panic attacks, followed by at least 1 month of persistent concern or worry about having additional attacks, worry about the consequences of attacks (cardiac arrest, stroke), or significant maladaptive alterations in behavior designed to avoid attacks.

Agoraphobia: Marked fear or avoidance of at least 2 of 5 situations : using public transportation, being in open spaces, being in enclosed spaces, standing in line or in a crowd, or being outside the home alone. The underlying fear is that escape might be difficult or help unavailable should panic-like or incapacitating symptoms emerge.

Therapy: SSRIs/SNRIs combined with CBT (interoceptive exposure); short-term sublingual or oral benzodiazepines (lorazepam, alprazolam) may abort acute severe attacks, but long-term maintenance is avoided due to tolerance, cognitive blunting, and dependence.

3. Post-Traumatic Stress Disorder (PTSD)

Etiological Precondition: Exposure to actual or threatened death, serious injury, or sexual violence through direct experience, witnessing, learning that it occurred to a close family member/friend, or repeated extreme exposure to aversive details (first responders).

Core Symptom Clusters (Duration > 1 Month):

Intrusion Symptoms: Recurrent, involuntary, distressing memories; traumatic nightmares; dissociative reactions (flashbacks in which the trauma feels recurring); intense physiological distress at reminders.

Avoidance: Persistent avoidance of distressing memories, thoughts, feelings, or external reminders (people, places, conversations) associated with the event.

Negative Alterations in Cognitions & Mood: Inability to remember key aspects of trauma (dissociative amnesia), persistent distorted blame of self or others, pervasive negative emotional state (fear, horror, guilt), detachment from others, anhedonia.

Alterations in Arousal & Reactivity: Irritable behavior, angry outbursts, reckless self-destructive behavior, hypervigilance, exaggerated startle response, concentration deficits, sleep disturbances.

Acute Stress Disorder: Requires at least 9 of 14 trauma-related symptoms across intrusion, negative mood, dissociation, avoidance and arousal, causing significant distress/impairment for 3 days to 1 month ; duration alone does not establish the diagnosis.

Treatment: Trauma-focused CBT (TF-CBT), Eye Movement Desensitization and Reprocessing (EMDR); first-line pharmacotherapy: SSRIs (sertraline, paroxetine). Prazosin (an alpha-1 adrenergic antagonist) is uniquely effective in reducing trauma-related nightmares and sleep fragmentation by suppressing central noradrenergic hyperactivation.

4. Obsessive-Compulsive Disorder (OCD)

Phenomenology: Characterized by obsessions (recurrent, persistent, intrusive, unwanted thoughts, urges, or images causing marked anxiety) and/or compulsions (repetitive behaviors such as handwashing, checking, ordering, or mental acts like counting, praying, silently repeating words performed to neutralize obsession-induced anxiety according to rigid rules). Recognized as egodystonic (distressing and recognized as irrational by the patient, unlike egosyntonic obsessive-compulsive personality disorder).

Treatment: First-line psychotherapy is Exposure and Response Prevention (ERP) . First-line pharmacotherapy requires high-dose SSRIs (e.g., fluoxetine 60-80 mg daily, sertraline 200 mg daily). Second-line agent is the tricyclic antidepressant Clomipramine (a potent serotonin reuptake inhibitor).

Substance Misuse & Acute Withdrawal in the Caribbean Context

Substance misuse poses severe public health challenges in the Caribbean. Alcohol remains the most pervasive drug of abuse, driving trauma and domestic morbidity. Crack cocaine and cannabis toxicity are frequent emergency room presentations.

Alcohol Withdrawal Syndrome: Neurobiology & Clinical Stages

Pathophysiological Mechanism: Alcohol acutely enhances inhibitory GABA-A signalling and inhibits excitatory NMDA signalling. Prolonged exposure produces compensatory reduced GABA-A function and increased NMDA activity/receptor expression . Abrupt reduction or cessation unmasks this excitatory state, producing autonomic hyperactivity, tremor, seizures and delirium.

Timeline of Alcohol Withdrawal

Stage 1: Minor Withdrawal (6 to 12 Hours post-cessation): Tremulousness (fine hand tremor), insomnia, generalized anxiety, nausea, vomiting, diaphoresis, mild tachycardia, and systolic hypertension.

Stage 2: Alcoholic Hallucinosis (12 to 24 Hours post-cessation): Visual, auditory, or tactile hallucinations (seeing animals or insects, hearing voices). Critical Clinical Feature: The patient's sensorium remains clear and fully oriented , distinguishing this from delirium tremens.

Withdrawal Seizures (About 8 to 48 Hours post-cessation, peaking near 24 hours): Generalized tonic-clonic convulsions. Typically singular or a brief flurry of 2 to 3 seizures. Post-ictal period is brief; status epilepticus is rare (< 3%). These are acute symptomatic (provoked) seizures , not by themselves evidence of chronic epilepsy. Treat withdrawal with benzodiazepines; routine phenytoin is ineffective unless a separate seizure disorder requires it.

Stage 4: Delirium Tremens (DTs) (48 to 96 Hours post-cessation; can last up to 7 days): Life-threatening medical emergency with historically a 5% to 15% mortality rate. Characterized by severe disorientation, profound delirium , fluctuating consciousness, vivid hallucinations (zoopsia), marked agitation, and severe autonomic hyperarousal (fever > 38.5°C, profuse drenching diaphoresis, tachycardia > 120 bpm, labile hypertension, tachypnea).

Clinical Management: The CIWA-Ar Protocol & Pharmacotherapy

The CIWA-Ar Scale: This 10-item scale supports symptom-triggered treatment in communicative patients without delirium ; local treatment thresholds commonly start around 8–10 . Assess prior seizures/DTs and other risk factors separately: a low current score does not exclude serious withdrawal risk. Do not use CIWA-Ar during delirium ; use an objective protocol such as RASS/MINDS , close observation and individualized IV benzodiazepines.

Benzodiazepine Regimen: Symptom-triggered dosing is preferred when reliable assessment and trained monitoring are available and can reduce medication exposure. Use an individualized fixed-dose or front-loading regimen when symptom scoring is unreliable/infeasible or severe withdrawal warrants it, with respiratory and sedation monitoring.

Long-Acting Benzodiazepines: Diazepam (10 to 20 mg PO) or Chlordiazepoxide (25 to 50 mg PO) repeated hourly until CIWA-Ar < 8. Long-acting active metabolites provide smooth self-tapering and protect against rebound seizures.

Hepatic Failure / Cirrhosis / Elderly: Use Lorazepam (1 to 2 mg PO/IV) or Oxazepam (15 to 30 mg PO) [Mnemonic: LOT – Lorazepam, Oxazepam, Temazepam]. These agents undergo direct hepatic glucuronidation without phase I cytochrome P450 oxidation, preventing toxic drug accumulation and hepatic encephalopathy.

Wernicke-Korsakoff Syndrome: Prompt Thiamine and Glucose Treatment

Etiology: Severe thiamine (vitamin B1) deficiency resulting from chronic malnutrition, impaired gastrointestinal absorption, and reduced hepatic storage in alcohol-dependent patients. Thiamine is an indispensable cofactor for transketolase, pyruvate dehydrogenase, and alpha-ketoglutarate dehydrogenase in cerebral glucose metabolism. Deficiency causes selective necrosis of the mamillary bodies, periventricular nuclei, and dorsomedial thalamus .

Clinical Triad of Acute Wernicke Encephalopathy:

Acute Encephalopathy: Global confusion, apathy, disorientation, inattention.

Gait Ataxia: Cerebellar vestibulocerebellar dysfunction presenting with a wide-based, staggering gait.

Oculomotor Abnormalities: Bilateral horizontal nystagmus, bilateral abducens (cranial nerve VI) palsy, conjugate gaze palsies.

Korsakoff Syndrome: The chronic, largely irreversible neuropsychiatric sequela occurring in untreated Wernicke's, characterized by severe anterograde and retrograde amnesia and confabulation (spontaneous fabrication of false memories without conscious intent to deceive).

RESUSCITATION: Suspected Wernicke encephalopathy requires prompt high-dose parenteral thiamine (e.g. IV thiamine 200–500 mg every 8 hours , following the local protocol). In a hypoglycaemic patient, give glucose immediately and thiamine concurrently when available; do not withhold glucose while waiting for thiamine . Continue thiamine during nutritional treatment because untreated deficiency can cause persistent neurological injury. At-risk alcohol-dependent patients also need thiamine prophylaxis.

Cocaine Intoxication & Sympathomimetic Toxicity

Mechanism: Blocks presynaptic reuptake of dopamine, norepinephrine, and serotonin, producing massive sympathetic nervous system hyperactivation.

Clinical Features: Severe agitation, mydriasis, diaphoresis, hyperthermia, tachycardia, and severe hypertension.

Life-Threatening Complications: Acute coronary vasospasm, myocardial infarction, aortic dissection, hemorrhagic/ischemic stroke, ventricular arrhythmias, and rhabdomyolysis.

Emergency Management: High-dose intravenous benzodiazepines (lorazepam 2 to 4 mg IV) are first-line therapy to blunt central sympathetic outflow, reduce blood pressure, control heart rate, and relieve psychomotor agitation. Intravenous nitroglycerin or phentolamine (nonselective alpha-adrenergic antagonist) treats refractory coronary vasospasm or malignant hypertension.

BETA-BLOCKER CAUTION: Avoid pure beta-blockers such as propranolol or metoprolol as initial treatment of acute cocaine-related hypertension/ischemia; coronary vasoconstriction may worsen. Benzodiazepines and vasodilators are preferred. This is not an absolute prohibition of every beta-blocker: ASAM/AAAP allows specialist consideration of an agent with alpha-1 blockade (e.g. labetalol) for persistent hyperadrenergic symptoms after initial treatment. Seek toxicology/cardiology advice; life-threatening cocaine vasospasm is treated with vasodilators, not beta-blockade.

Opioid Overdose & Acute Withdrawal

Overdose Triad: Central nervous system depression (coma), pinpoint pupils (miosis) , and severe respiratory depression (respiratory rate < 8-10 breaths/min). Note: Mydriasis may occur in late-stage severe cerebral hypoxia or with meperidine.

Emergency Reversal: Intravenous, intramuscular, or intranasal Naloxone (pure competitive mu-opioid receptor antagonist). Titrate in small increments (0.04 to 0.4 mg) to restore adequate spontaneous respiration without precipitating acute severe withdrawal. Because naloxone has a short half-life (30 to 90 minutes) compared to many opioids (e.g., methadone half-life 24-36 hours), continuous monitoring for rebound respiratory depression is mandatory.

Opioid Withdrawal: Diaphoresis, lacrimation, rhinorrhea, yawning, piloerection ('cold turkey'), pupil dilation, intense abdominal cramps, vomiting, diarrhea, and severe myalgias. Highly distressing but not intrinsically life-threatening .

Life-Threatening Psychotropic Drug Emergencies & Extrapyramidal Side Effects

Diagnostic / Clinical Feature Neuroleptic Malignant Syndrome (NMS) Serotonin Syndrome (SS)

Precipitating Pharmacotherapy Dopamine D2 receptor antagonists (Haloperidol, Fluphenazine, SGAs) or abrupt withdrawal of dopaminergic therapy (levodopa or direct dopamine agonists) Combinations of serotonergic agents (SSRIs, SNRIs, MAOIs, TCAs, Tramadol, Linezolid, MDMA, Dextromethorphan)

Clinical Onset Insidious / Evolving over days to weeks (typically 3 to 9 days after drug initiation or dose escalation) Rapid / Acute onset within hours (typically < 12 to 24 hours after drug administration)

Neuromuscular Hallmarks Severe "Lead-Pipe" generalized rigidity , hyporeflexia, cogwheeling Neuromuscular excitation: CLONUS (spontaneous, inducible, ocular) , hyperreflexia (prominent in lower limbs), tremors

Thermoregulatory Signs Severe hyperpyrexia (typically > 38.0°C to > 40.0°C / 104°F) Hyperthermia (often mild to moderate; can exceed 40.0°C in severe cases)

Pupils & Bowel Sounds Normal pupils; decreased / absent bowel sounds Mydriasis (dilated pupils) ; hyperactive bowel sounds / diarrhea

Laboratory Hallmarks Massive elevation of serum Creatine Kinase (CK > 1000 - 100,000 U/L) , leukocytosis (15-30 x 10^9/L), elevated AST/LDH, myoglobinuria CK and leukocytes vary; severe toxicity may cause rhabdomyolysis with marked CK elevation , AKI and metabolic acidosis

Specific Medical Antidote Dantrolene (muscle relaxant) and Bromocriptine / Amantadine (dopamine agonists) Cyproheptadine (serotonin 5-HT2A antagonist) and IV Benzodiazepines

The Hunter Serotonin Toxicity Criteria

Serotonin Syndrome is diagnosed clinically using the validated Hunter Criteria. In the presence of a serotonergic agent, the patient must exhibit at least one of the following:

  • Spontaneous clonus
  • Inducible clonus PLUS agitation or diaphoresis
  • Ocular clonus PLUS agitation or diaphoresis
  • Tremor PLUS hyperreflexia

Hypertonia PLUS temperature > 38.0°C PLUS ocular or inducible clonus Diagnostic Pearl: Clonus (spontaneous, inducible, or ocular) is the single most sensitive and specific clinical differentiator of Serotonin Syndrome from NMS.

Extrapyramidal Side Effects (EPS): Timeline, Manifestations & Management

Acute Dystonic Reaction (Hours to Days): Sustained, involuntary, painful muscle contractions. Manifests as torticollis (spasmodic neck twisting), oculogyric crisis (fixed upward deviation of the eyes), trismus, retrocollis, and laryngeal dystonia (respiratory emergency). High risk with typical FGAs (haloperidol). Treatment: Immediate intravenous or intramuscular Anticholinergic / Antihistaminic therapy: Diphenhydramine (50 mg IV/IM) or Benztropine (1 to 2 mg IV/IM) , producing rapid resolution within 10 to 15 minutes.

Akathisia (Days to Weeks): Subjective feeling of inner motor restlessness, severe anxiety, and an irresistible urge to move the limbs. Patients pace continuously, rock from foot to foot, or shift repeatedly in chairs. Frequently misdiagnosed as worsening psychotic agitation, leading to fatal increases in neuroleptic dose. Associated with heightened suicide risk. Treatment: First-line therapy is a centrally acting beta-blocker: Propranolol (10 to 40 mg PO three times daily) ; second-line: low-dose benzodiazepines or reducing antipsychotic dose.

Parkinsonism / Pseudoparkinsonism (Weeks to Months): Striatal D2 blockade mimicking Parkinson's disease: bradykinesia, resting pill-rolling tremor, cogwheel rigidity, masked facies, festinating gait, and sialorrhea. Treatment: Centrally acting anticholinergics ( Benztropine 1 to 2 mg PO daily or Trihexyphenidyl 2 to 5 mg PO daily ) or switching to an atypical antipsychotic. Dopamine precursors (levodopa) are contraindicated as they exacerbate underlying psychosis.

Tardive Dyskinesia (TD) (Months to Years): Potential consequence of chronic, long-term D2 receptor blockade, resulting in postsynaptic dopamine receptor upregulation and supersensitivity in the nigrostriatal pathway. Characterized by involuntary, repetitive, choreoathetoid movements of the face, tongue, and lips: tongue protrusion ('fly-catcher' tongue), lip smacking, puckering, chewing motions, grimacing, and choreiform movements of the extremities and trunk. Treatment: Discontinue typical antipsychotics or switch to Clozapine (which has minimal D2 affinity and does not worsen TD). Anticholinergic drugs must be strictly withdrawn because they worsen tardive dyskinesia. First-line pharmacotherapy for established TD utilizes VMAT2 Inhibitors (Valbenazine, Deutetrabenazine) , which deplete presynaptic dopamine vesicles.

Loading diagram... Acute Alcohol Withdrawal Assessment & CIWA-Ar Resuscitation Algorithm